DailyIQ
|
Last updated2 minutes ago

PRAX·Praxis Precision Medicines Inc.

$280.40
-3.16 (-1.11%)
Overnight$280.14-0.26 (-0.09%)
High
$289.47
Open
$289.47
Market Cap
7.92B
52W High
$392.70
Low
$272.17
P. Close
$280.40
P/E
-
52W Low
$50.31
Fwd P/E
-30.34
DailyIQ Est.
$740.54
Inst. Ownership
0.2%
Short Interest
13.43%
Days to Cover
14.9
Technical Score (1D)
27
BEARISH
News Sentiment
57
BULLISH
On Oct 6, BTIG analyst Kambiz Yazdi maintained a Buy rating on Praxis Precision Medicine (PRAX) and raised the price target from $810 to $826. The upgrade reflected confidence in the company’s pipeline and recent clinical milestones. The new target suggested a potential upside for investors, though it was not described as a transformative catalyst. The report indicated that BTIG’s assessment was based on the company’s progress in developing its therapeutic portfolio. No other developments were reported for that date.
LOW TARGET
$188 -32.9%
2 analysts
MEAN TARGET
$644 +129.7%
8 analysts
HIGH TARGET
$1201 +328.7%
16 analysts
PRICE RANGE
$188.00 - $1201.00
SB / B / H / S / SS
9/13/2/1/1
DAILYIQ EST.
$740.54 (+164.3%)
Bought (1Y)
0 shares
$0
Sold (1Y)
11,600 shares
$3.6M
Souza MarcioChief Executive Officer
Gift2,600 shares2026-07-08
Souza MarcioChief Executive Officer
Gift20,521 shares2026-07-08
DeSimone Jill-
Option Exercise3,034 shares2026-06-24
DeSimone Jill-
Option Exercise8,566 shares2026-06-24
DeSimone Jill-
Sell837 shares2026-06-24
View full insider trading history →
39/ 100
Bearish
Overall: Bearish
✕Revenue declining year over year
✕Negative operating cash flow
✓Manageable liabilities relative to assets
Current Ratio
10.22x
Return on Equity
-34.5%
View full financials →

EPS

EstBeatMiss
$-3.67$-3.58$-3.50$-3.41$-3.32Q3'25Q3'26
QtrEstActual+/−
Q3'26$-3.63 - -
Q3'25$-3.49$-3.36+3.7%

Revenue

EstBeatMiss
$-0.15$-0.075$0$0.075$0.15Q3'25Q3'26
QtrEstActual+/−
Q3'26$0 - -
Q3'25 - $0 -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

PRAX Stock Snapshot

BEARISH27/100
$280.14−$0.26 (0.1%)
Market cap
7.92B
Day range
$272.17 – $289.47
News sentiment
57/100 · Neutral
Analyst target
$643.58 (+129.7%)
Consensus
Buy · 26 analysts
52-week range+456.8% off low · -28.7% from high
$50.31$392.70
Price $280.14 DailyIQ Est. $740.54

Price action on PRAX is defensive - rallies are being sold rather than extended. At this size, a single catalyst moves the stock further than it would a larger peer.

Sector Rotation

Is money rotating into or out of PRAX's sector?

Praxis Precision Medicines Inc. sits in the Health Care sector, currently ranked 8th of 12 GICS sectors by relative-strength rotation score (lagging). Within its narrower Biotechnology industry group, PRAX ranks 10th of 15 tracked industries, lagging.

Sector rank
#8 of 12
Sector state
Lagging
Sector rotation score
0
Industry rank
#10 of 15

Options Market

What is the options market pricing for PRAX?

CallsPuts

For Praxis Precision Medicines Inc.'s nearest expiry (2026-10-16, 9 days out), open interest is roughly balanced between puts and calls (put/call ratio of 0.90), with at-the-money implied volatility around 90.1%. The options market is pricing roughly a ±14.5% move by that expiry — a range of about $268.29–$359.11.

Put/call ratio (2026-10-16)
0.90
ATM implied volatility
90.1%
Total open interest
676
Expected move by 2026-10-16
±14.5% ($268.29–$359.11)

Analyst Rating Changes

Are analysts turning bullish or bearish on PRAX?

HC Wainwright & Co. most recently reiterated its rating on Praxis Precision Medicines Inc. to Buy on Sep 24, 2026 with a price target of $1201. Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
HC Wainwright & Co. — Buy
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Sep 24, 2026HC Wainwright & Co.ReiteratedBuy$1201
Sep 24, 2026NeedhamReiteratedBuy$582
Aug 21, 2026Goldman SachsMaintainedBuy$470 → $575
Aug 7, 2026RBC CapitalMaintainedOutperform$449 → $462
Aug 7, 2026Wells FargoMaintainedEqual-Weight$323 → $362
Aug 6, 2026NeedhamMaintainedBuy$575 → $582
Jul 29, 2026BTIGReiteratedBuy$810
Jul 13, 2026Goldman SachsInitiatedBuy$447
Jun 29, 2026NeedhamMaintainedBuy$537 → $575
Jun 18, 2026RBC CapitalInitiatedOutperform$449
Jun 2, 2026OppenheimerMaintainedOutperform$750 → $650
Jun 2, 2026Truist SecuritiesMaintainedBuy$715 → $616

Held by These ETFs

PRAX is a top holding in these ETFs tracked on DailyIQ — bar length shows portfolio weight.

News Sentiment Analysis

Sentiment gathered from recent headlines

57/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
BTIG analyst Kambiz Yazdi maintained a Buy rating on Praxis Precision Medicine (PRAX) and raised the price target from $810 to $826. The upgrade reflects confidence in the company’s pipeline and recent clinical milestones. The new target suggests a potential upside for investors, though it is not a transformative catalyst.
What did this article say?
Praxis Precision Medicine (PRAX) released its second‑quarter 2026 financial results and hosted an earnings call on October 5. The company provided a transcript of the call, outlining its financial performance and strategic priorities. No significant deviations from guidance or material events were disclosed during the session. The announcement serves as a routine update for investors and analysts.
What did this article say?
Praxis Precision Medicines, Inc. (PRAX) announced on October 1, 2026 that its Compensation Committee granted restricted stock unit awards covering 3,478 shares to fourteen new non‑executive employees. The awards are part of the company’s 2024 Inducement Plan and are intended to attract and retain talent. The announcement was issued via a Globe Newswire release and does not indicate any immediate financial or strategic impact on the company.
What did this article say?
HC Wainwright & Co. analyst Douglas Tsao reaffirmed a Buy rating for Praxis Precision Medicine and maintained a $1,201 price target. The upgrade signals confidence in the company’s growth prospects and valuation. The firm’s guidance and product pipeline were cited as key drivers for the positive outlook.
What did this article say?
Needham analyst Ami Fadia reaffirmed a Buy rating for Praxis Precision Medicine (PRAX) on September 24, maintaining the $582 price target. The upgrade signals confidence in the company’s growth prospects and product pipeline. The recommendation reflects a positive outlook on PRAX’s market positioning and potential upside, though it is not deemed transformative.
What did this article say?
Praxis Precision Medicines (PRAX) has experienced a more than 1,000% share price increase since April 2025, driven by landmark clinical results for ulixacaltamide and relutrigine. Both compounds have achieved statistically significant outcomes and are slated for 2026/2027 PDUFA dates, targeting large CNS markets with combined peak sales potential exceeding $15 billion. The company’s $1.4 billion cash reserve supports a robust commercial buildout, reduces near‑term capital risk, and leaves room for potential out‑licensing and priority review vouchers, sustaining upside expectations.

Technical Analysis

Real-time indicators across multiple timeframes

27
BEARISH
Technical indicators reflect the latest computed signal mix for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
1 tracked managers · $16.85M combined position · 0 adding, 0 trimming, 1 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Citadel Advisors LLC• Hold50,3310.18%$16.85M2026-09-02
Q2 2026 flow:50.3K sh bought ($16.85M)0 sh sold ($0)net +50.3K sh (+$16.85M)
View full institutional holdings history →
Congressional Trading Activity
1 disclosed trades · ~$8.0K est. traded value · 1 buys, 0 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-07-302026-09-04
View full congressional trading history →

Discover More

BIIB
Biogen Inc.
$222.51
-0.23%
WAT
Waters Corporation
$436.43
-0.01%
VEA
Vanguard FTSE Developed Markets ETF
$71.17
+0.07%
ISRG
Intuitive Surgical, Inc.
$405.10
+0.06%
CYTK
Cytokinetics Incorporated
$61.35
-0.02%
XLV
Health Care Select Sector SPDR Fund
$167.32
+0.14%
PFE
Pfizer Inc.
$27.50
+0.04%
DXCM
DexCom, Inc.
$83.39
-0.01%
APGE
Apogee Therapeutics Inc.
$135.11
+0.01%
REGN
Regeneron Pharmaceuticals, Inc.
$738.72
+0.00%